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1. Introduction 
A large portion of patients with epilepsy without other obvious organ disease die 
unexpectedly. Epidemiological studies have estimated the rate of unexpected death in 
patients with epilepsy up to 24 times higher as compared to the general population (Ficker 
et al., 1998). However, in contrast to a significantly increased risk of sudden death in 
epilepsy patients, the underlying causes and pathophysiological mechanisms leading to 
sudden death are not well understood. This important problem is clinically identified as 
sudden unexplained death in epilepsy (SUDEP). Of note, SUDEP does not include death 
after prolonged seizures (e.g. status epilepticus) or due to other organ disease which 
excludes common cardio-pulmonary pathology. SUDEP occurs frequently in patients with 
idiopathic epilepsy with an estimated prevalence of 2% to 18% (Nashef et al., 2007; Tomson 
et al., 2008). It has been hypothesized that SUDEP and certain types of seizures may initiate 
a pathological signal to the heart, which subsequently triggers cardiac dysrhythmias and 
sudden death in epilepsy (Jehi & Najm, 2008; Surges et al., 2009). Alternatively, dysfunction 
of fast ion transport mechanisms, which directly control membrane excitability within the 
context of either the brain or the heart, may directly cause both neuronal or cardiac 
dysrhythmias. Importantly, if certain genetic defects in ion channel genes coexisted in the 
brain and heart, this may constitute a candidate mechanism of SUDEP and potentially 
precipitate life-threatening cardiac dysrhythmias (Nashef et al., 2007). Indeed, recent work 
has identified ion channelopathies in the context of generalized epilepsy that coexist in the 
brain and the heart. For the first time, defined molecular mechanisms of coexisting brain 
and heart dysrhythmias have been shown in genetically engineered rodent models with 
patient mutations which reproduce both neuronal and cardiac patient phenotypes. This 
article focuses on previous perspectives and recent insights about molecular epilepsy 
mechanisms, which underlie both dangerous dysrhythmias in the brain and heart. In 
addition, novel targeted treatment rationales based on molecular and cellular mechanisms 
of dysrhythmias are discussed. 
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2. Can existing genetic epilepsy mechanisms explain unexpected death? 
Epilepsy is an episodic dysrhythmia of electrical brain activity in the cerebral cortex marked 
by abnormal neuronal network synchronization. Approximately 20 genes with major effects 
on susceptibility to epilepsy have been associated with different seizure syndromes. These 
epileptogenic genes define distinct as well as common modulatory pathways of neuronal 
network activity. One group of genetic variants appears to destabilize neuronal signaling 
through defects which affect the neurophysiology of electrical membrane excitability and 
synaptic transmission. Another group of genetic variants causes neurodevelopmental effects 
which perturb the balance between inhibitory and excitatory circuits. Unfortunately, none of 
the genetically defined epilepsy mechanisms can readily explain molecular pathways which 
lead to cardiac dysrhythmias as a hypothetical cause of unexpected death in epilepsy. 
Due to a high rate of SUDEP in primary epilepsy patients with generalized seizures, it might 
be important to consider how epilepsy genes are identified and within which 
pathophysiological context a genetic defect has been further characterized. The following 
two principal strategies exist: 1) a candidate gene is identified in the context of inherited 
disorders in patients or animal models and 2) an incidental phenotype identifies a genetic 
epilepsy syndrome following targeted mutagenesis in animal models. Indeed, both 
strategies have contributed to a growing list of genes linked to inherited epilepsies. The 
diversity of distinct phenotypes and their causative gene mutations provides important 
clues both to a gene’s physiological function as well as to a behavioral disease mechanism 
which might surprisingly reveal overlap with cardiac dysrhythmias. The list of 
epileptogenic genes spans from intrinsic membrane proteins underlying cell membrane 
excitability to nuclear transcription factors which control the fate of developing neuronal 
networks. Accordingly, mechanisms that underlie epilepsy may range from abnormal action 
potential firing to developmental abnormalities of specific neural circuits. Within the context 
of unexpected death in epilepsy, mechanisms which directly cause electrical membrane 
dysfunction and thereby alter fast action potential signaling seem promising to explain 
either or both brain and heart dysrhythmias. Indeed, recent insight from genetically 
engineered animal models has uncovered previously unknown epilepsy syndromes and 
genes in the context of cardiac dysrhythmia syndromes. 
2.1.1 Consideration of previous perspectives to explain SUDEP 
Risk factors for SUDEP include early onset of epilepsy from age 20 to 40 years, generalized 
seizures, resistance to anticonvulsant drug therapy, and poor patient compliance (Hitiris et 
al., 2007). Importantly, several clinical studies have documented abnormalities of the heart 
rhythm in SUDEP patients suggesting the possibility of co-existing or even synergistic 
neuro-cardiogenic mechanisms (Britton et al., 2006; Johnson et al., 2009; Nei et al., 2000; 
Opherk et al., 2002; Zijlmans et al., 2002). Indeed, sudden death caused by dysrhythmia of 
the heart (in cardiovascular sciences also referred to as arrhythmia) represents a frequent 
cause of electrical organ dysfunction in the general population. The phenotype of cardiac 
arrhythmia has been linked to a large spectrum of gene variants that include multiple ion 
channel genes (see 2.1.2). Therefore, a hypothetical mechanism of SUDEP could be that the 
identical ion channel gene expressed in the brain and the heart becomes dysfunctional due 
to a mutation, and causes a combined neuro-cardiogenic syndrome including unexpected 
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death in epilepsy. Is there sufficient evidence for such a combined neuro-cardiogenic 
mechanism of SUDEP in patients? 
In epilepsy patients and also in SUDEP victims a spectrum of cardiac dysrhythmias has 
been reported including arrhythmias of the atria as well as life-threatening ventricular 
arrhythmias. Thus, genetic ventricular arrhythmia syndromes may provide an opportunity 
to gain mechanistic insight about SUDEP if brain seizures coexisted. However, the originally 
proposed pathophysiological mechanism which starts from a primary neuronal defect 
which leads to secondary cardio-respiratory arrest and dangerous cardiac arrhythmias 
could not be established in patients. As alternative, if an epileptogenic gene defect were 
expressed both in the brain and heart, this would allow for investigation of the underlying 
dysrhythmia mechanisms separately in the brain and heart, and be tested for mechanistic 
links between cortical hyperexcitability and sudden unexpected death by unknown neuro-
cardiogenic mechanisms. Before I outline such novel epilepsy mechanisms with potential 
mechanistic links between the brain and the heart, I will review existing evidence about 
gene defects associated either with brain or heart dysrhythmias, to assess if common 
denominators exist which may contribute to seizure susceptibility. 
2.1.2 Genes of fast neuronal signaling associated with epilepsy 
The identification of genes that determine the risk of epilepsy has very important 
implications for patients, clinical diagnosis, and basic research. Within this context it is 
important to consider that molecular testing for genetic defects in epilepsy at current is 
mainly used by hypothesis driven research for the following two reasons: 1) genetic defects 
such as mutations can significantly increase our understanding of the basic mechanisms 
underlying seizure susceptibility; and 2) genetic defects which cause seizures in patients 
often lead to important research insights about the fundamental role of a protein which has 
previously not been fully understood in a neurophysiological context. Readers with a 
special interest in clinical diagnostic testing may also refer to the up-to-date special report of 
the International League Against Epilepsy (ILAE) Genetics Commission (Ottman et al.,2010).  
In epilepsy, the majority of gene defects affect voltage- and/or ligand-gated ion channels 
that have been linked to paroxysmal network synchronization in seizure syndromes. These 
epileptogenic genes include both the pore-forming and regulatory subunits of Na+, K+, and 
Ca2+ channels of the plasma membrane, as well as ligand-gated channels modulated by 
GABA, Ach, and other ligands. Additionally, certain transport proteins  are affected by 
genetic defects include the Na+/K+-ATPase and an important glucose transporter of the 
brain. While analysis of some of these epileptogenic gene mutations in heterologous cell 
expression systems has provided important insights, it is important to note that considerable 
gaps remain in our understanding how a specific channelopathy may result in increased 
network excitability and abnormal network synchronization in the brain. Therefore, it is 
without doubt very challenging to mechanistically understand epilepsy syndromes 
associated with other paroxysmal neuronal disorders or even other organ dysfunction like 
cardiac arrhythmias as a hypothetical cause of SUDEP. Table 1 on the following page 
summarizes confirmed genetic epilepsy syndromes, which have been mostly linked to 
defects in ion transport. Although we do not understand the precise mechanisms of 
abnormal network synchronization behind most of the defects listed in table 1, a common 
denominator of these epilepsy genes are fast neurophysiological signaling mechanisms. 
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Seizure syndromes that start within the first year of life 
Syndrome Gene Protein Defect References 
Benign familial neonatal 
seizures 
KCNQ2 Kv7.2 I(K) ↓ (Biervert et al., 1998; 
Charlier et al., 1998; 
Singh et al., 1998) 
KCNQ3 Kv7.2 I(K) 
Benign familial neonatal-
infantile seizures 
SCN2A Nav1.2 I(Na) 
(Berkovic et al., 2004; 
Heron et al., 2002) 
Syndromes with prominent febrile seizures 
Syndrome Gene Protein Defect References 
Dravet syndrome (severe 
myoclonic epilepsy of infancy)
SCN1A Nav1.1 
I(Na) 
(Claes et al., 2001; 
Nabbout et al., 2003) 
Genetic (generalized) epilepsy 
with febrile seizures plus 
(GEFS+) 
SCN1A Nav1.1 (Escayg et al., 2000) 
SCN1B ǃ1 SU (Wallace et al., 1998) 
GABRG2 Ǆ2 SU 
GABAA 
receptor 
(Baulac et al., 2001) 
Childhood absence epilepsy 
with febrile seizures 
GABRG2 Ǆ2 SU (Kananura et al., 2002; 
Wallace et al., 2001) 
Idiopathic generalized epilepsies 
Syndrome Gene Protein Defect References 
Early-onset absence epilepsy SLC2A1 GLUT1 
Glucose 
uptake ↓ (Suls et al., 2009) 
Juvenile myoclonic epilepsy GABRA1 ǂ1 SU GABAA 
receptor ↓
(Cossette et al., 2002; 
Suzuki et al., 2004) 
Focal epilepsies 
Syndrome Gene Protein Defect References 
Autosomal dominant 
nocturnal frontal lobe 
epilepsy 
CHRNA4 ǂ4 SU 
nACh 
receptor 
(Steinlein et al., 1995) 
CHRNB2 ǃ2 SU (De Fusco et al., 2000) 
CHRNA2 ǂ2 SU (Aridon et al., 2006) 
Epilepsies associated with other paroxysmal disorders 
Syndrome Gene Protein Defect References 
Generalized epilepsy and 
paroxysmal dyskinesia 
KCNMA1 KCa1.1 I(K) (Du et al., 2005) 
Epilepsy with paroxysmal 
exercise-induced dyskinesia 
SLC2A1 GLUT1 
Glucose 
uptake ↓ 
(Suls et al., 2008; 
Weber et al., 2008) 
Absence epilepsy and 
episodic ataxia 
CACNA1A Cav2.1 
I(Ca, P/Q) 
↓ 
(Imbrici et al., 2004; 
Jouvenceau et al., 
2001) 
Focal epilepsy and episodic 
ataxia 
KCNA1 Kv1.1 I(K) 
(Eunson et al., 2000; 
Spauschus et al., 1999; 
Zuberi et al., 1999) 
Familial hemiplegic migraine 
and epilepsy 
ATP1A2 
Na+,K+-
ATPase 
I(K) ↓ 
(Deprez et al., 2008; 
Vanmolkot et al., 
2003) 
Table 1. Genes identified in idiopathic epilepsy syndromes. Abbreviations: I, indicates ionic 
current (type); ↑ gain-of-function; ↓ loss-of-function. 
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To compare the above identified mechanisms of epilepsy syndromes with those of 
paroxysmal arrhythmia syndromes of the heart, we will next review confirmed monogenetic 
disorders of the heart, which have also been linked to ion transport dysfunction. Please note, 
that for clarity this chapter is focused on genes underlying different forms of membrane 
transport defects in epilepsy or cardiac arrhythmias. 
2.2.1 Genetic defects underlying cardiac dysrhythmias 
Europe and North America have a high annual incidence of sudden cardiac death (SCD) 
amounting to up to 100 per 100.000 in the general population (Byrne et al., 2008; Chugh et 
al., 2004). SCD is defined as a sudden and unexpected pulseless primary cardiac event 
(Chugh et al., 2008). Despite the presence of modern resuscitation chains for out-of-hospital 
SCD the overall survival rate is only 4.6% (Nichol et al., 2008). SCD is the outcome of 
electrical heart disease that manifests as fast ventricular arrhythmias or pulseless electrical 
activity. In a significant number of patients, cardiac dysrhythmia and SCD occur unexpected 
without prior warning and without a clinically identifiable triggering mechanism. 
Therefore, cardiac dysrhythmia and SCD risk prediction remain a major challenge. 
However, understanding of molecular mechanisms has significantly advanced for inherited 
cardiac channelopathies that predispose to SCD (Lehnart et al., 2007). 
Cardiac ion channelopathies provide important rationales to understand mechanisms of 
cardiac dysrhythmias and the risk of SCD. The most common cardiac genetic channelopathies 
manifest as delayed ventricular repolarization seen as a prolonged QT interval by surface 
electrocardiogram (ECG), fast ventricular arrhythmias, recurrent syncope (loss of 
consciousness), and seizures. The Long QT syndrome (LQTS) is mostly caused by genetic ion 
channel defects resulting in abnormal prolongation of the cardiac action potential in 
approximately 1 in 2000 mutation carriers (Roden, 2008). Depending on the underlying gene 
defect and incompletely understood environmental factors, LQTS mutation carriers have a 
significantly increased risk for fatal ventricular arrhythmias and SCD. The majority of 
identified LQTS mutations cause ion channel dysfunction through mutations of pore-forming 
ǂ or accessory ǃ subunits as summarized in table 2. A recently discovered LQTS variant 
phenotype is Sudden Infant Death Syndrome (SIDS) caused by some of the same gene defects. 
Among known cardiac ion channelopathies K+ and Na+ channel mutations of the KCNQ1, 
KCNH2, and SCN5A genes stand out, because these cause the great majority of LQTS cases. 
Although seizures occur in LQTS mutation carriers, these were previously considered to 
represent secondary events due to reduced blood perfusion of the brain during cardiac 
arrhythmias. However, it can be difficult to distinguish between a phenotype of syncope 
from cardiac dysrhythmias and primary neurogenic seizure auras with or without 
myoclonus (McKeon et al., 2006). In addition, simultaneous electroencephalogram (EEG) 
and ECG recordings revealed a surprisingly high prevalence of up to 44% of different types 
of cardiac arrhythmias in individuals with primary epileptic seizures (Britton et al., 2006; 
Johnson et al., 2009; McKeon et al., 2006; Nei et al., 2000; Opherk et al., 2002; Zijlmans et al., 
2002). Recently, seizure phenotypes have been reported in approximately one third of 
confirmed LQTS mutation carriers (including 22% with the most prevalent form LQTS1) 
suggesting that LQTS genes may cause neuronal hyperexcitability independent from cardiac 
arrhythmias (Johnson et al., 2009). In addition, seizures have been reported in up to half of 
confirmed RYR2 mutation carriers affected by stress-induced ventricular arrhythmias 
(Postma et al., 2005). Of note, in a given mutation carrier neuronal seizures and cardiac 
arrhythmias may occur simultaneously, or a brain dysrhythmia may secondarily trigger a 
cardiac arrhythmia through unknown mechanisms. 
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Sudden infant death syndrome (SIDS): starting within the first year of life 
Syndrome Gene Protein Defect References 
SIDS1 KCNH2 Kv11.1 I(Kr) ↓ (Arnestad et al., 2007) 
SIDS2 KCNQ1 Kv7.1 I(Ks) ↓ (Moss et al., 2007) 
SIDS3 KCNJ2 Kir2.1 I(K1) ↓ (Arnestad et al., 2007) 
SIDS4 SCN5A Nav1.5 I(Na) ↑ (Plant et al., 2006; Van 
Norstrand et al., 2008) 
Long QT syndrome (LQTS): prominent lengthening of the electrocardiogram QT interval 
Syndrome Gene Protein Defect References 
LQTS1 KCNQ1 Kv7.1 I(Ks) ↓ (Moss et al., 2007; Wang et al., 
1996)
LQTS2 KCNH2 Kv11.1 I(Kr) ↓ (Curran et al., 1995) 
LQTS3 SCN5A Nav1.5 I(Na) ↑ (Bennett et al., 1995; Wang et 
al., 1995)
LQTS5 KCNE1 ǃ SU I(Ks) ↓ (Sanguinetti et al., 1996; 
Splawski et al., 1997) 
LQTS6 KCNE2 ǃ SU I(Kr) ↓ (Abbott et al., 1999) 
LQTS7 KCNJ2 Kir2.1 I(K1) ↓ (Bendahhou et al., 2003; 
Plaster et al., 2001) 
LQTS8 CACNA1C Cav1.2 ǂ1c I(Ca,L) ↑ (Splawski et al., 2005; 
Splawski et al., 2004) 
LQTS10 SCN4B ǃ4 SU I(Na) ↑ (Medeiros-Domingo et al., 
2007)
Short QT syndrome (SQTS): prominent shortening of the electrocardiogram QT interval 
Syndrome Gene Protein Defect References 
SQTS1 KCNH2 Kv11.1 I(Kr) ↑ (Brugada et al., 2004; Hong et 
al., 2005a)
SQTS2 KCNQ1 Kv7.1 I(Ks) ↑ (Bellocq et al., 2004; Hong et 
al., 2005b)
SQTS3 KCNJ2 Kir2.1 I(K1) ↑ (Priori et al., 2005) 
SQTS4 CACNA1C Cav1.2 ǂ1c I(Ca,L) ↓ (Antzelevitch et al., 2007) 
SQTS5 CACNB2 ǃ2b SU I(Ca,L) ↓ (Antzelevitch et al., 2007) 
Timothy Syndrome (TS) and Autism Spectrum Disorder
Syndrome Gene Protein Defect References 
TS1 CACNA1CA Cav1.2 ǂ1c I(Ca,L) ↑ (Splawski et al., 2004) 
TS2 CACNA1C Cav1.2 ǂ1c I(Ca,L) ↑ (Splawski et al., 2005) 
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
Syndrome Gene Protein Defect References 
CPVT1 RYR2 RyR2 
SR Ca leak 
↑
(Laitinen et al., 2001; Priori et 
al., 2001)
CPVT2 CASQ2 
Calsequestri
n
SR Ca leak 
↑
(Lahat et al., 2001; Postma et 
al., 2002)
CPVT3 KCNJ2 Kir2.1 I(K1) ↑ (Plaster et al., 2001; Tester et 
al., 2006)
Table 2. Genes identified in idiopathic ventricular arrhythmia syndromes. Abbreviations: I, 
indicates ionic current (type); SR, sarcoplasmic reticulum calcium store; ↑ gain-of-function; ↓ 
loss-of-function. 
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It is important to note that many genetic and phenotypic variations of cardiac 
channelopathy syndromes exist. In LQTS approximately 40% of family members who are 
confirmed carriers of a gene mutation are clinically silent with a normal or borderline QT 
interval (Bai et al., 2009; Hofman et al., 2007). In addition, some patients with borderline QT 
interval prolongation are negative for LQTS mutations, but positive for mutations linked to 
the syndrome CPVT (Tester et al., 2006; Tester et al., 2005). Furthermore, mutations in 
intronic regions have recently been identified as a cause of LQTS (Zhang et al., 2004). Of 
significance for molecular mechanisms, cardiac arrhythmias in LQTS1 and CPVT1 mutation 
carriers are both triggered by increased physical or emotional stress, indicating that the 
respective Kv7.1 and RyR2 defects may share the same regulatory pathways during 
arrhythmia triggers under control of the sympathetic nervous system (Lehnart et al., 2004). 
In contrast, LQTS3 mutation carriers experience cardiac arrhythmias during rest or sleep 
(Roden, 2008). Notably, for intermediate risk traits at the level of the general population 
genome-wide association studies have identified determinants of the QT interval including 
variants of the KCNQ1, KCNH2, and SCN5A genes (Albert et al.; Newton-Cheh et al., 2009). 
In analogy to the ILAE for epilepsy, the International Long QT Syndrome Registry facilitates 
insight and patient recommendations about genetic forms of cardiac arrhythmias (Moss & 
Schwartz, 2005). 
2.2.2 Synopsis of existing genetic dysrhythmia mechanisms in the brain and heart 
Excitability of the brain and heart is based on the same principles of ion transport. At the 
molecular level some of the same classes of ion channels, for example the SCN and KCNQ 
isoforms, exist in the brain and heart. However, comparison of tables 1 and 2 shows that 
previously established monogenic defects cannot readily provide a mechanistic association 
between neuronal and cardiac dysrhythmias. In addition, as outlined under 2.1.2 the 
prevailing research focus about a given organ disease like cardiac arrhythmias may 
introduce a phenotypic bias such that other organs like brain seizures may have not been 
comprehensibly studied. Indeed, prior to the age of genetic information epilepsy patients 
with frequent seizures were sometimes diagnosed with the syndrome of Catecholaminergic 
Polymorphic Ventricular Tachycardia (CPVT), however, the arrhythmias were thought to 
explain the seizure phenotype and epilepsy treatment was discontinued (Leenhardt et al., 
1995). Within this context it is important to realize that the differential diagnosis of brain 
and heart seizure phenotypes is of historical significance and extends to famous scholars 
and patients including Napoleon Bonaparte (Osler, 1903). Thus, one must consider that 
accurate differentiation between neuronal and cardiac seizure phenotypes is challenging in 
patients and may need patience (McKeon et al., 2006).  
Despite these difficulties, initial clues that LQTS gene mutations may also cause seizures 
originating from the brain came from studies of the cardiac sodium channel Nav1.5. As 
outlined in table 2, SCN5A mutations cause LQTS including ventricular arrhythmias and 
SCD (Chen et al., 1998; Wang et al., 1995). In addition, Nav1.5 is expressed in the entorhinal 
cortex and the amygdala, and other limbic brain regions which have been associated with a 
low threshold for abnormal network synchronization and brain seizures (Hartmann et al., 
1999). Despite these early hypothetical associations, cardiac LQTS genes have subsequently 
not been mechanistically linked to the context of primary brain dysrhythmias. Therefore, 
despite a wealth of molecular and electrophysiological insights originating from genetic 
linkage studies, prediction and prevention of associated brain and heart dysrhythmias 
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remain little understood. Clearly, additional and likely complex studies which integrate 
multiple investigative levels are needed, in particular to explore underlying mechanisms of 
potentially co-existing brain and heart dysrhythmias, and to elucidate mechanistic links 
between electrical brain and heart phenotypes. As will be discussed next, recent basic 
science research studies suggest an unprecedented level of complexity concerning ion 
transport dysfunction and molecular crosstalk within the context of excitable organ disease 
of the brain and heart. 
2.3 Novel genetic mechanisms of associated brain and heart dysrhythmias 
Completely new epilepsy mechanisms have recently been identified in mouse models with 
human cardiac arrhythmia symptoms of confirmed mutation carriers. Of note, through a 
bench-to-bedside approach these experimental studies strongly suggest that combined 
neuro-cardiogenic disease mechanisms exist. These neuro-cardiogenic syndromes may in 
principle also underlie SUDEP in patients. Notably, combined neuro-cardiogenic 
mechanisms have been implicated earlier in the genetic Timothy syndrome, a rare ion 
channelopathy causing multiple organ phenotypes including cardiac arrhythmias, autism, 
mental retardation and seizures. Patients with Timothy syndrome have de novo mutations 
of splice exon 8A of the main cardiac L-type Ca2+ channel pore-forming ǂ-subunit Cav1.2 
resulting in intracellular Ca2+ overload, which occurs in the heart and brain (Splawski et al., 
2005). While the patient phenotype of Timothy syndrome is very complex due to multiple 
coexisting organ and metabolic disease processes, which makes elucidation of specific 
molecular SUDEP mechanisms difficult, it emphasizes the importance to consider both the 
brain and heart in seizure phenotypes. 
Abnormal intracellular Ca2+ homeostasis has also been identified for a different 
epileptogenic mechanism due to mutations of the cardiac ryanodine receptor type 2 (RyR2). 
RyR2 forms the ǂ-subunit of the tetrameric intracellular Ca2+ release channel, and is highly 
expressed in the heart and brain. In 2001 RyR2 missense mutations were identified in 
patients with syncope, seizures and SCD (Laitinen et al., 2001; Priori et al., 2001). Due to the 
characteristic dependence of the cardiac phenotype on physical and/or emotional stressors, 
the syndrome has been called Catecholaminergic Polymorphic Ventricular Tachycardia type 
1 (CPVT1) (Priori et al., 2001). The phenotype of stress-induced cardiac arrhythmias is 
dependent on heart rate and reproducible for diagnostic purposes by exercise ECG testing 
in RyR2 mutation carriers (Lehnart et al., 2004). It has been assumed that in CPVT the 
syncope and seizures are not of primary neuronal origin, but due to decreased blood 
perfusion of the brain during ventricular arrhythmias (also known as Stokes-Adams 
attack)(Leenhardt et al., 1995). However, under experimentally controlled conditions 
behavioural and electrophysiological analysis of knockin mice with RyR2 missense 
mutations have shown that generalized seizures can occur independent from cardiac 
arrhythmias (Lehnart et al., 2008). As will be discussed below, RyR2 mutant mice provided 
the first evidence that the same molecular ion channel defect can cause generalized seizures 
and ventricular arrhythmias. RyR2 mutations cause abnormal intracellular Ca2+ signals in 
neurons and cardiac myocytes, which represents a novel genetic candidate mechanism of 
generalized seizures and of unexpected death in epilepsy. 
Recently, a second mechanism of generalized seizures and cardiac arrhythmias has been 
identified in mice with KCNQ1 mutations, which affects the pore-forming ǂ-subunit of the 
cardiac delayed rectifier K+ channel Kv7.1 (table 2). Kv7.1 forms the slow repolarizing 
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membrane current I(Ks), which is active during the repolarizing phases 2 and 3 of the 
cardiac action potential. Kv7.1 loss-of-function mutations increase cardiac action potential 
duration (Wang et al., 1996; Wang et al., 1999; Westenskow et al., 2004). Kv7.1 mutations 
underlie the most common form of the cardiac Long QT syndrome (LQTS1) leading to 
syncope, stress-induced arrhythmias, seizures and SCD. Mouse models harbouring patient 
missense mutations of the KCNQ1 gene have reproduced key aspects of the human cardiac 
LQTS1 phenotype (Casimiro et al., 2004). In addition, the LQTS1 mouse models reproduce 
sensory defects of the inner ear hair cells, which also express Kv7.1 channels (Casimiro et al., 
2004; Kubisch et al., 1999). As will be discussed below, Noebels and colleagues have recently 
re-evaluated the same KCNQ1 knockin mice with patient missense mutations and identified 
a previously unknown generalized seizure phenotype (Goldman et al., 2009). 
The same gene defects which have originally been identified in patients with cardiac 
arrhythmia phenotypes in the LQTS1 and CPVT1 syndromes, have recently been associated 
with generalized seizure phenotypes in the respective KCNQ1 and RYR2 knock in mouse 
models with patient mutations (Goldman et al., 2009; Lehnart et al., 2008). While LQTS1 
mutations of Kv7.1 lead to prolongation of the cardiac action potential, CPVT1 mutation of 
RyR2 result in abnormal cardiac membrane depolarizations following the regular cardiac 
action potential, referred to as delayed afterdepolarizations (DADs). Notably, the clinical 
phenotypes of LQTS1 and CPVT1 patients both include syncope and seizures, which as 
mentioned earlier can be difficult to differentiate (McKeon et al., 2006). Indeed, in LQTS1 
seizures have been reported in up to one-third of genotype-confirmed patients (Johnson et 
al., 2009) and in CPVT1 in up to half of confirmed RyR2 mutation carriers (Postma et al., 
2005). Thus, genetic patient studies have shown that both LQTS1 and CPVT1 mutation 
carriers exhibit symptoms of neuronal hyperexcitability. 
Despite significant conceptual advances through recent identification of ion channel gene 
variants, which cause combined seizure and arrhythmia syndromes, many questions remain 
unanswered and require further study. These questions concern the specific brain regions 
and neuron types, which show a decreased threshold for aberrant network synchronization, 
such that prolonged depolarization or delayed repolarization may initiate primary brain 
seizures. In addition, arrhythmias in LQTS1 and CPVT1 are characteristically modulated by 
the autonomous nervous system. If the autonomous nervous system is also affected by the 
same genes and modulates the phenotype defects needs further exploration. The following 
chapters will discuss recent advances in ion channel studies related to epilepsy and 
particular insight about combined neuro-cardiogenic phenotypes and mechanisms which 
may link the dysrhythmia phenotypes of the two separate organs. Already, these recent 
insights have motivated further research about diagnostic strategies to improve risk 
prediction and prevention in patients with seizure disorders of unknown origin. In addition, 
novel therapeutic strategies targeting the underlying molecular mechanisms are under 
development. Therefore, the following chapters will also discuss the translation of novel 
seizure mechanisms in neuro-cardiogenic syndromes into therapeutic rationales. 
2.3.1 Ryanodine receptor mutations cause generalized seizures 
Seizure models using pharmacological inducers have found intracellular Ca2+ abnormalities 
in inhibitory interneurons and astrocytes during seizure like activity (Tian et al., 2005). In 
addition, inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) intracellular Ca2+ release 
channels, which localize to intracellular ER Ca2+ stores, have been associated with seizures 
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in mice (Street et al., 1997). However, a mechanistic relationship between dysfunction of 
intracellular Ca2+ release channels and seizures has not been established. Ca2+ is an 
important neuronal signaling molecule and intracellular Ca2+ release channels are an 
important source including IP3R1-3 isoforms (Mignery et al., 1989; Street et al., 1997) and the 
related ryanodine receptor isoforms (RyR1-3)(Henzi & MacDermott, 1992; Kostyuk & 
Verkhratsky, 1994). Interestingly, mutation carriers with RyR2 mutations have been shown 
to exhibit syncope, seizures and cardiac arrhythmias (Postma et al., 2005). 
RyR2 is the major Ca2+ release channel of the heart. Over 100 different RYR2 mutations have 
been associated with Catecholaminergic Polymorphic Ventricular Tachycardia type 1 
(CPVT) and ventricular arrhythmias (table 2). Importantly, early clinical descriptions of 
childhood CPVT documented initial presentations with seizures, loss of consciousness, 
convulsions, and involuntary incontinence in approximately 50% of patients (Leenhardt et 
al., 1995). A similar presentation has been confirmed in RYR2 mutation carriers who have 
also presented with seizures in 50% of patients (Postma et al., 2005). Additionally, patients 
with CPVT2 caused by calsequestrin2 mutations also have seizures (Lahat et al., 2001). 
Indeed, RyR2 is highly expressed in the brain including the hippocampus dentate gyrus 
granule cell layer and the CA1-3 pyramidal cell layers (figure 1). These hippocampal areas 
have been associated with pharmacologically stimulated ryanodine receptor dysfunction 
and generalized tonic-clonic seizure activity (Mori et al., 2005). 
We created knockin mice with RyR2 patient missense mutations (R2474S and N2386I) which 
have been linked to autosomal-dominant CPVT in families (Priori et al., 2001). The 
heterozygous RYR2 mutant mice spontaneously developed recurring generalized tonic-
clonic seizures during arousal as well as in the absence of obvious environmental changes. 
Generalized myoclonic seizures in RYR2 mutant mice exhibited a rapid progression from 
freezing to partial behavioral abnormalities to generalized myoclonic and tonic-clonic 
behavior (Lehnart et al., 2008). Video-assisted analysis showed that generalized seizure 
activity lasted between 20 and 120 seconds. Simultaneous EEG-ECG recording showed 
bilateral voltage discharges including higher frequency sharp spikes and waves, however, 
no cardiac arrhythmias (figure 1; lower, left). These data unambiguously show that at least 
some of the seizures in RYR2 mutation carriers are of primary neuronal origin. Importantly, 
recent studies have confirmed the a seizure phenotype in patients including RYR2 mutation 
carriers (Johnson et al.,2009; Nagrani et al.,2011). 
Pharmacological challenge with the seizure inducing drugs 4-aminopyridine and caffeine 
showed increased seizure susceptibility in RYR2 mutant mice. Generalized tonic-clonic 
seizures occurred significantly earlier in RYR2 mutant as compared to wild-type control 
mice. In addition, RYR2 mutant mice showed a faster progression to more severe seizure 
stages. Moreover, the seizure phenotype was found in two independently generated RYR2 
mutant knockin mouse strains (R2474S and N2386I). 
Extracellular local field potential (LFP) recording in acute hippocampal brain slices revealed 
significantly increased excitability following 4-aminopyridine treatment in RYR2 mutant 
brain tissue as compared to wild-type control tissue sections (Lehnart et al., 2008). LFP 
recording showed discharges with higher burst frequency and duration in CA3 network 
regions of RYR2 mutant brain tissue (figure 1; lower, center). Increased hippocampal CA3 
seizure activity of RYR2 mutant cells has been confirmed with confocal Ca2+ imaging of the 
somata in the principal cell layer in hippocampal brain slices (figure 1; lower, right). The Ca2+ 
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Fig. 1. Epileptogenic phenotype of RYR2 knockin mice with orthologous patient mutations. 
Top: In situ RyR2 hybridization of a sagittal brain section from an adult male mouse brain. 
Red colour indicates maximal RyR2 mRNA expression as evidenced in the hippocampus 
and cerebral cortex.  Image was prepared with the Allen Brain Atlas: http:www.brain-
map.org; Seattle, WA: Allen Institute for Brain Science © 2006. Bottom, left: simultaneous 
EEG-ECG recording of awake heterozygous RyR2-R2474S mouse during start of generalized 
myoclonic seizure. Bottom, center: extracellular local field potential (LFP) recording of 
seizure-like events from CA3 region of hippocampal slices incubated in 10 μM 4-
aminopyridine from heterozygous RyR2-R2474S mutant adult mouse showing abnormally 
complex and sustained bursting activity as compared to wild-type control (not shown). 
Bottom, right: continuous confocal fluo-4 Ca2+ fluorescence imaging of RyR2-R2474S mutant 
CA3 principal cell layer showing synchronized seizure bursting activity in low Mg2+ (0.5 
mM)/high K+ (8.5 mM) solution. Each trace represents the cytosolic Ca2+ signal from a local 
region of interest corresponding to the somata of three neighbouring CA3 pyramidal 
neurons. Reproduced from (Lehnart et al., 2008) with permission by “The American Society 
of Clinical Investigation” (www.jci.org) provided by Copyright Clearance Center, 2011. 
imaging experiments revealed increased neuronal network synchronization in the CA3 region 
consistent with increased bursting activity of CA3 cells by LFP recording. In addition, single-
channel bilayer recording, which were isolated from hippocampal tissue, showed a gain-of-
function defect of RyR2-R2474S mutant channels consistent with abnormal intracellular Ca2+ 
leak, and consistent with abnormal confocal Ca2+ bursting activity in RyR2-R2474S brain slices 
(Lehnart et al., 2008). Because heterozygous RyR2-R2474S mice exhibited recurrent generalized 
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tonic-clonic seizures and bilateral cortical EEG discharges in the absence of cardiac 
arrhythmias and in addition stress-induced ventricular arrhythmias in the absence of seizure 
activity, we proposed that RyR2 mutations cause a combined neuro-cardiogenic syndrome 
(Lehnart et al., 2008). As CPVT mutation carriers experience a very high mortality rate at 
young age which has been estimated between 33% and 50% at 35 years (Lehnart et al., 2004; 
Priori et al., 2002), RYR2 is is a potential candidate gene for SUDEP. 
2.3.2 Potassium channel mutations and generalized seizures 
Unexpectedly, a LQTS patient study found that one third of confirmed mutation carriers have 
seizures including the relatively common KCNQ1 mutation, indicating a potential link 
between cardiac arrhythmias and epilepsy (Johnson et al., 2009) However, KCNQ1 expression 
in the brain is incompletely understood partially due to conflicting data. Importantly, KCNQ1 
mRNA and Kv7.1 protein expression, as well as expression of the accessory ǃ-subunit minK 
have recently been confirmed in the human and mouse brain in the cortex and hippocampus 
(Goldman et al., 2009). Immunofluorescence staining as shown in figure 2 (left) further 
demonstrated that Kv7.1 is expressed within important hippocampal pathways including 
pyramidal neurons of the CA1 and CA3 regions, granule cells of the dentate gyrus, and hilar 
interneurons (Goldman et al., 2009). In addition, Kv7.1 positive neurons were found in the 
cortex, the thalamus, as well as brain stem nuclei which contribute parasympathetic outflow to 
the heart by the vagus nerve (Goldman et al., 2009). Thus, Kv7.1 protein expression has been 
confirmed in specific brain regions of the adult mouse, which are of potential significance for 
epileptogenesis. 
 
 
Fig. 2. Epileptogenic phenotype of KCNQ1 knockin mice with orthologous patient 
mutations. Left: Kv7.1 immunofluorescence image of adult mouse brain section of the 
hippocampus dentate gyrus/hilar region showing positively stained granule cell layer (gc), 
CA3 pyramidal cell layer (sp), and hilar interneurons (arrows). Scale bar indicates 50 μm. 
Right top: EEG recording of a heterozygous Kv7.1-T311I mutant mouse during onset of a 
spontaneous convulsive seizure attack. Right bottom: Detail of combined EEG and ECG 
recording of a homozygous Kv7.1-A340I mutant mouse showing bilateral interictal 
discharges over the temporal cortex with coinciding AV conduction block in the ECG. 
Reproduced from (Goldman et al.,2009) with permission by "The American Association for 
the Advancement of Science" (www.sciencemag.org) provided by Copyright Clearance 
Center, 2011. 
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Two knockin mouse lines (T311I and A340E) with KCNQ1 point mutations corresponding to 
human mutation carriers have previously been shown to reproduce the cardiac phenotype 
of LQTS1 (table 2) including ventricular arrhythmias (Casimiro et al., 2004). In addition, 
video-monitoring showed spontaneously occurring generalized seizures in one third of 
heterozygous mutant KCNQ1 knockin mice, but never in wild-type control animals 
(Goldman et al., 2009). In addition, all heterozygous KCNQ1 mutant animals showed partial 
seizures lasting less than 10 secs. The generalized seizures were characterized by sudden 
arrest of activity, followed by tonic extension and whole body convulsive movements, and 
simultaneous EEG showed bilateral rhythmic high voltage sharp wave discharges evolving 
into a higher frequency rhythmic discharges (figure 2, right top). In contrast, the partial 
seizures were characterized by behavioural arrest without prominent clonic movements, 
and the EEG showed coinciding low-voltage rhythmic slow activity interspersed with spike 
and wave discharges. 
Registration of cortical activity by EEG in KCNQ1 knockin mice with Kv7.1 mutations 
revealed epileptiform spike discharges and simultaneous ECG recording showed abnormal 
cardiac events consistent with slowing of the heart rhythm (Goldman et al., 2009). Awake, 
freely moving KCNQ1 knockin mice exhibited frequent bilateral interictal epileptiform 
discharges including sharp waves and spikes, and prolonged runs of temporal focal slow 
waves. Interestingly, simultaneous ECG recording showed that approximately one fourth of 
cortical EEG discharges coincided with cardiac ECG abnormalities including prolonged 
beat-to-beat intervals, extrabeats, and even asystolie (complete block of ventricular rhythm) 
as shown figure 2 (right bottom). Of note, 62% of ECG abnormalities coincided with cortical 
EEG changes. Simultaneous EEG-ECG abnormalities are in agreement with autonomic 
dysregulation of impulse conduction as previously reported in SUDEP patients (Nei et al., 
2004). In addition SCD was found in one homozygous T311I mouse, which died 
spontaneously from cardiac asystolie following prolonged seizures (Goldman et al., 2009). 
2.4 Novel, targeted treatment strategies 
Significant progress has been made to understand epilepsy through studies of monogenetic 
syndromes and the associated molecular mechanisms of seizures. Epilepsy genes have been 
identified in human mutations carriers and increasingly through animal models with 
distinct seizure phenotypes. Notably, the majority of identified epilepsy genes encode ion 
channels and associated subunits. These important insights have provided candidate 
treatment targets based on identified cellular and molecular mechanisms of epileptogenesis. 
In addition, epilepsy is increasingly recognized as heterogeneous syndrome of co-existing 
and even multi-organ syndromes, for example the neuro-cardiogenic syndromes discussed 
above. Advanced understanding of basic and complex seizure mechanisms has triggered 
development of new diagnostic and therapeutic approaches some of which are summarized 
here in the context of ion channelopathies. 
Existing pharmacological and surgical therapies have been estimated to control seizure 
symptoms in approximately 60% of epilepsy patients. Therefore, development of novel 
therapies remains a major challenge. If one considers combined neuro-cardiogenic 
syndromes in the context of pharmacotherapies several important perspectives can be 
drawn from the mechanistic insights discussed in earlier chapters.  Individuals at risk with 
SUDEP represent a major clinical challenge, and the gray area of undetected cardiac 
arrhythmia risk is potentially high due to lack of adequate screening strategies and 
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awareness. Recent ECG studies showed that every fifth epilepsy patients experiences 
abnormally slow heart rhythms during seizures, culminating in 16% with asystolie which is 
potentially lethal (Rugg-Gunn et al., 2004). For confirmed KCNQ1 mutation carriers 
implantable pacemaker therapy should be considered in the context of abnormally slow 
heart rhythms, and considering the possible changes of brainstem parasympathetic outflow 
to the heart recently identified in knockin mice with Kv7.1 mutations (Goldman et al., 2009). 
As ǃ-blockers are therapeutically recommended in LQTS1 in confirmed KCNQ1 mutation 
carriers with the potential side effect of slow heart rates, it is important to carefully monitor 
the heart rate behaviour in affected patients (Roden, 2008). 
In addition, we have developed novel RyR2-specific compounds which permeate the blood-
brain barrier and inhibit both neuronal seizures and cardiac arrhythmias (Lehnart et al., 
2008). Different from conventional ion channel blockers, RyR2 stabilizing compounds like 
S107 have no effect on physiological channel function and do not alter intracellular Ca2+ 
signaling (Lehnart, 2007). In addition, S107 has not shown any significant side effects against 
other ion channels or enzymes in large screening panels (Lehnart et al., 2008). Similar to 
LQTS1, ǃ-blocker therapy is recommended in patients with CPVT1 and confirmed RYR2 
mutation carrier status due to the characteristic dependence of cardiac arrhythmias on 
sympathetic outflow to the heart. In summary, the neuro-cardiological implications of 
idiopathic epilepsies are potentially important in mutation carriers, and comprehensive 
phenotype and genotype risk profiling may lead to improved therapy and prevention of 
fatal arrhythmias in affected epilepsy patients. 
2.5 Summary of combined syndromes of neuronal and cardiac ion channelopathies 
Recent studies have for the first time identified previously unrecognized brain ion 
channelopathies as the neurobiological basis of generalized seizures. While the epilepsy 
phenotypes represent primary brain discharges, the same molecular defects precipitate life-
threatening cardiac arrhythmias. The following mechanisms have been proposed to underlie 
epilepsy in combined neuro-cardiogenic syndromes: 
Kv7.1 dysfunction in KCNQ1 mutation carriers with LQTS1 may alter the propensity of 
neurons and cardiac myocytes to repolarize following depolarization by an action potential. 
This results in a decreased repolarization capacity in the brain and heart. In the brain, a 
decreased repolarization capacity during action potential firing may result in seizures and 
brainstem autonomic dysfunction of parasympathetic outflow leading to heart rhythm block 
and asystolie for example at the level of the cardiac AV node. Dysfunction of brain stem 
parasympathetic outflow to the cardiac sinus and atrioventricular nodes as a cause of 
asystolie in epilepsy expands previously described arrhythmia mechanisms, since fast 
ventricular arrhythmias are characteristically triggered by increased sympathetic outflow in 
KCNQ1 mutation carriers. Because Kv7.1 mutations can cause dangerous cardiac 
arrhythmias, KCNQ1 is a molecular candidate mechanism and risk factor of SUDEP. These 
findings establish KCNQ1 in neuronal hyperexcitability and epileptogenesis. Hundreds of 
KCNQ1 mutations have been identified mostly leading to loss-of-function phenotypes. 
However, the correlation between Kv7.1 channel defects and the clinical phenotype in 
different organs is variable, and not all mutations may cause epilepsy or only when a 
permissive background or environmental condition exists. 
RYR2 mutations appear to cause increased neuronal burst activity of the hippocampal CA3 
region and seizure activity as evidenced by synchronous bursting Ca2+ signals of principal 
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cells in hippocampal brain slices. Indeed, increased neuronal network synchronization in 
the CA3 region is consistent with a gain-of-function defect of RyR2-R2474S mutant channels 
which exhibit defective closure (Lehnart et al., 2008). A hippocampal seizure mechanism is 
also consistent with the progressive, generalized tonic-clonic seizures and bilateral cortical 
EEG discharges documented in RYR2 mutant mice with patient mutations.  
3. Conclusion 
Recent advances in ion channelopathy studies related to epilepsy have achieved important 
new insights about combined neuro-cardiogenic phenotypes, and mechanisms which may 
link dysrhythmia phenotypes of the brain and heart through the autonomic nervous system. 
Already, these insights have motivated further research about diagnostic strategies to 
improve risk prediction and prevention in patients with seizure disorders of unknown 
origin. In addition, novel therapeutic strategies which target the underlying molecular 
mechanisms are under development. Despite significant new mechanistic insight about 
Kv7.1 and RyR2 ion channel mutations as the cause of combined neuro-cardiogenic seizure 
and arrhythmia syndromes, many questions remain unanswered and require further study. 
These questions concern the specific brain regions and neuron types, which show a 
decreased threshold for aberrant network synchronization, such that prolonged 
depolarization or delayed repolarization may initiate primary brain seizures. In addition, 
arrhythmias in LQTS1 and CPVT1 are characteristically modulated by the autonomous 
nervous system. If the autonomous nervous system is also affected by the same gene 
mutations and exacerbates the cardiac and/or neuronal phenotypes needs further 
exploration through multidisciplinary research teams. Clearly, the new insights about 
neuro-cardiogenic dysrhythmias should motivate both clinicians and researchers to 
critically inquire complex phenotypes beyond the borders of a given research discipline. 
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